A Phase 1 interventional study of nacresertib and Placebo in Healthy Volunteers, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives for this 2 Part study are to assess the safety, tolerability, and pharmacokinetics following single ascending oral doses of nacresertib in healthy adult participants (Part 1) and to assess the safety, tolerability, and pharmacokinetics following multiple ascending oral doses in healthy adult participants (Part 2).
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Participants will receive a single dose of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Participants will receive a single dose of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Participants will receive a single dose of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Participants will receive a single dose of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Participants will receive multiple doses of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Participants will receive multiple doses of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Participants will receive multiple doses of nacresertib or Placebo
Drug: nacresertib · Drug: Placebo
Oral
Oral
Maximum Observed Plasma Concentration (Cmax) of nacresertib
Cmax of nacresertib
Time frame: Up to Day 19
Time to Cmax (Tmax) of nacresertib
Tmax of nacresertib
Time frame: Up to Day 19
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of nacresertib
AUCt of nacresertib
Time frame: Up to Day 19
AUC From Time 0 to the Time Infinity (AUCinf) of nacresertib
AUCinf of nacresertib
Time frame: Up to Day 19
Part 2 Only: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of nacresertib
AUCtau of nacresertib
Time frame: Up to Day 14
Terminal Phase Elimination Rate Constant (Beta) of nacresertib
Beta of nacresertib
Time frame: Up to Day 19
Terminal Phase Elimination Half-Life (t1/2) of nacresertib
t1/2 of nacresertib
Time frame: Up to Day 19
Dose Normalized Cmax
Dose Normalized Cmax
Time frame: Up to Day 19
Dose Normalized AUCs
Dose Normalized AUCs
Time frame: Up to Day 19
Number of Participants Experiencing Adverse Events (AEs)
Any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
Time frame: 74 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in May 2026, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nacresertib